Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 7, 2023, Tandem Diabetes Care, Inc. ("Tandem" or the "Company") and David B. Berger, the Company's Executive Vice President and Chief Operating Officer, determined that he will be stepping down from his current position effective December 31, 2023. Mr. Berger is responsible for the Company's clinical, quality and regulatory functions, having served in a variety of leadership roles throughout his tenure at Tandem, including the historical oversight of legal, customer technical support and operations. Tandem anticipates that Mr. Berger will provide transition advisory services to the Company through 2024, and the Company will make a subsequent filing to disclose the terms of any related agreement.





2


Attachments

Disclaimer

Tandem Diabetes Care Inc. published this content on 13 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 November 2023 11:05:15 UTC.